# EDGAR Filing Document

**Accession Number:** 0001832038
**File Stem:** 0001193125-25-288171
**Filing Date:** 2025-11
**Character Count:** 7007
**Document Hash:** 94f15772e241fd2727ece392b4dff2a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-288171.hdr.sgml**: 20251119

**ACCESSION NUMBER**: 0001193125-25-288171

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251119

**DATE AS OF CHANGE**: 20251119

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Invivyd, Inc.
- **CENTRAL INDEX KEY:** 0001832038
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 851403134
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92804
- **FILM NUMBER:** 251499720

**BUSINESS ADDRESS:**
- **STREET 1:** 209 CHURCH STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06510
- **BUSINESS PHONE:** (781) 819-0080

**MAIL ADDRESS:**
- **STREET 1:** 209 CHURCH STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06510

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Adagio Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20201112
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adimab, LLC
- **CENTRAL INDEX KEY:** 0001545672

**ORGANIZATION NAME:**
- **EIN:** 800669559
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 7 LUCENT DRIVE
- **CITY:** LEBANON
- **STATE:** NH
- **ZIP:** 03766
- **BUSINESS PHONE:** 603-643-7110

**MAIL ADDRESS:**
- **STREET 1:** 7 LUCENT DRIVE
- **CITY:** LEBANON
- **STATE:** NH
- **ZIP:** 03766

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_a.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**Invivyd, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**00534A102**

*(CUSIP Number)*

**Philip Chase**<br>Adimab, LLC<br>7 Lucent Drive<br>Lebanon NH 03766<br>(603) 643-7110

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/17/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **00534A102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Adimab, LLC** | Name of reporting person<br>**Adimab, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**20454490.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**20454490.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**20454490.00** | Aggregate amount beneficially owned by each reporting person<br>**20454490.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.8%** | Percent of class represented by amount in Row (11)<br>**8.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Limited Liability Company

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
Invivyd, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
209 Church Street, New Haven, CT, 06510

This Amendment No. 4 ("Amendment No. 4") amends and supplements the Schedule 13D originally filed by Adimab, LLC (the "Reporting Person") with the Securities and Exchange Commission (the "Commission") on March 30, 2022, as amended and supplemented by Amendment No. 1 thereto, filed with the Commission on April 26, 2022, Amendment No. 2 thereto, filed with the Commission on June 24, 2022 and Amendment No. 3 thereto, filed with the Commission on January 22, 2024 (the "Original 13D," and together with this amendment, the "Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 4 have the meanings ascribed to them in the Original 13D.  This Amendment is being filed to report that the beneficial ownership of Common Stock by the Reporting Person has decreased by more than 1% as a result of the sales reported in Item 5.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 of the Schedule 13D is hereby amended and restated as follows:
(a) Amount beneficially owned: 21,687,906; Percent of Class: 8.8%.
The above percentage is based on 233,122,834 shares of Common Stock outstanding as of October 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

**(b)**
(b) The Reporting Person has sole voting and sole dispositive power with respect to all of the shares of Common Stock that it beneficially owns.

**(c)**
On November 17, 2025, the Reporting Person sold 1,233,416 shares of Common Stock at a weighted average price of $3.0026 per share in a series of open market transactions. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.045 per share.  The Reporting Person undertakes to provide to the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Adimab, LLC

**Signature:** /s/ Philip Chase

**Name/Title:** Philip Chase, Chief Executive Officer

**Date:** 11/19/2025